NHS Digital Data Release Register - reformatted
West Hertfordshire Teaching Hospitals NHS Trust projects
2 data files in total were disseminated unsafely (information about files used safely is missing for TRE/"system access" projects).
MR1258 - Early Rheumatoid Arthritis in the United Kingdom (ERAN) — DARS-NIC-147877-QXH0L
Opt outs honoured: No - consent provided by participants of research study, Identifiable, Yes, No (, )
Legal basis: Informed Patient consent to permit the receipt, processing and release of data by the HSCIC, Health and Social Care Act 2012 – s261(2)(c), Informed Patient consent to permit the receipt, processing and release of data by NHS Digital, , Informed Patient consent to permit the receipt, processing and release of data by NHS Digital; Informed Patient consent to permit the receipt, processing and release of data by NHS Digital
Purposes: No (NHS Trust)
Sensitive: Sensitive, and Non Sensitive, and Non-Sensitive
When:DSA runs 2012-03-14 — 2027-03-13 2016.06 — 2020.03.
Access method: Ongoing, One-Off
Data-controller type: WEST HERTFORDSHIRE HOSPITALS NHS TRUST, WEST HERTFORDSHIRE TEACHING HOSPITALS NHS TRUST
Sublicensing allowed: No
- MRIS - Cause of Death Report
- MRIS - Cohort Event Notification Report
- MRIS - Flagging Current Status Report
- MRIS - Members and Postings Report
- MRIS - Personal Demographics Service
- MRIS - Scottish NHS / Registration
Early Rheumatoid Arthritis in the United Kingdom – A prospective observational study of the secondary care management of patients with early rheumatoid arthritis in the United Kingdom (ERAN).
To establish a database of long-term clinical data in order to monitor management and outcomes of patients with early RA in the UK. It is envisaged that this resource will contribute to the development of good clinical practice/guidelines and clinical governance issues.
To facilitate the design and execution of nested studies by providing statistical information required for study design and permitting the identification of potential research subjects.
The following main primary endpoints will be evaluated:
Diagnosis of RA
RA medication usage and reasons for change
Prevalence of concurrent pathology
Co-morbidity & Mortality